Database for
Therapeutic Antibodies
Therapeutic Antibodies
| Entry ID | 1958 |
| INN | Pagibaximab |
| Status | Terminated |
| Drug code(s) | BSYX-A110, hu96-110 |
| Brand name | None |
| mAb sequence source | mAb chimeric |
| General Molecular Category | Naked monospecific |
| Format, general category | Full length Ab |
| Format details | None |
| Isotype (Fc) | IgG1 |
| Light chain isotype | kappa |
| Linker | None |
| Ave. DAR | None |
| Conjugated/fused moiety | None |
| Discovery method/technology | None |
| Target(s) | Staphylococcal lipoteichoic acid |
| Indications of clinical studies | Staphylococcal Sepsis in very low birth weight neonates |
| Primary therapeutic area | Infectious diseases |
| Most advanced stage of development (global) | Terminated at Phase 2/3 |
| Status | Inactive |
| Start of clinical phase (IND filing or first Phase 1) | July 02, 2001 |
| Start of Phase 2 | March 15, 2003 |
| Start of Phase 3 | |
| Date BLA/NDA submitted to FDA | |
| Year of first approval (global) | None |
| Date of first US approval | |
| INN, US product name | None |
| US or EU approved indications | None |
| Company | Sunol Molecular |
| Licensee/Partner | Biosynexus Incorporated, GSK |
| Comments about company or candidate | None |
| Full address of company | 2810 N COMMERCE PKY, MIRAMAR, FL 33025, United States North America United States of America https://www.sbir.gov/node/320095 |
Target is “Staphylococcal lipoteichoic acid” according to https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2704668/
| Anticipated events | None |
| Factor(s) contributing to discontinuation | None |